Key references: Drug therapy for gastroparesis

Parkman HP, Van Natta ML, Abell TL, McCallum RW, Sarosiek I, Nguyen L, et al. Effect of nortriptyline on symptoms of idiopathic gastroparesis: the NORIG randomized clinical trial. JAMA 2013;310(24):2640-9. https://www.ncbi.nlm.nih.gov/pubmed/24368464
Strijbos D, Keszthelyi D, Smeets FGM, Kruimel J, Gilissen LPL, de Ridder R, et al. Therapeutic strategies in gastroparesis: results of stepwise approach with diet and prokinetics, Gastric Rest, and PEG-J: A retrospective analysis. Neurogastroenterol Motil 2019;31(6):e13588. https://www.ncbi.nlm.nih.gov/pubmed/30947400
Therapeutic Goods Administration. Medicines safety update, volume 6, number 1, Feburary 2015: Metoclopramide and neurological adverse events. Aust Prescr 2015;38(1):26. https://www.tga.gov.au/publication-issue/medicines-safety-update-volume-6-number-1-february-2015
Therapeutic Goods Administration. Medicines safety update. Ondansetron and QTc interval prolongation - dosing change. Aust Prescr 2012;35(6):198-9. https://www.nps.org.au/australian-prescriber/articles/medicines-safety-update-10
Vijayvargiya P, Camilleri M, Chedid V, Mandawat A, Erwin PJ, Murad MH. Effects of promotility agents on gastric emptying and symptoms: a systematic review and meta-analysis. Gastroenterology 2019;156(6):1650-60. https://www.ncbi.nlm.nih.gov/pubmed/30711628